Neoadjuvant treatment by ECT in cutaneous malignant neoplastic lesions

Fabrizio, Tommaso; Cagiano, Luigi; Terlizzi, Francesca de; Grieco, Michele

doi:10.1016/j.bjps.2019.11.063

Cited by 7 publications

(8 citation statements)

References 33 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, ECT, after bleomycin was previously administered, obtained positive results in the local control of the disease, whereas other treatments, such as surgery or radiotherapy, would have been hazardous because of the high risk of side effects like ulceration, bleeding, infection, and delayed healing. Because ECT has already been discussed by several authors as a therapy growing in popularity for the treatment of cutaneous neoplasms also in first-line choices, it is worth extending the indications of ECT therapy to clinical situations that cannot otherwise be treated, such as other skin tumors, for example, unresectable metastases in melanoma or breast cancer or cylindromas of the scalp, as a adjuvant or palliative treatment [27][28][29]. Furthermore, we observed in our experience that ECT could be successful also in the management of the disease for those patients affected by advanced and widespread CKS cutaneous lesions (Figures 3 and 4).…”

Section: Discussionmentioning

confidence: 99%

Electrochemotherapy in Kaposi’s Sarcoma Patients: From the Gold Standard Strategy to Locally Advanced Cutaneous and Subcutaneous Lesions

Rullo,

Castellaneta,

D’Antonio

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

Electrochemotherapy (ECT) is one of the newest therapeutic strategies employed as a medical procedure for skin neoplasms’ treatment, especially for classic Kaposi’s sarcoma (CKS). The aim of this study was to demonstrate ECT clinical response and the local control of CKS disease. The primary endpoint was to value the worth and efficacy of this local therapy in CKS skin lesions’ treatment. In total, 19 CKS patients were enrolled, 14 males and 5 females with median age at diagnosis of 72. Complete response (CR) has been gained in 12 patients after first ECT attempt; meanwhile, 3 and 4 out of 19 patients obtained a partial response (PR), so they underwent a second and third ECT treatment, respectively. Clinical response was evaluated during the entire timeframe of the follow-up, which ranged between 3 months and 4 years with a median of 18 months. The control of CKS skin lesions still represents a challenge for surgeons and oncologists. Nevertheless, according to this and other authors’ recent experiences, ECT could be considered the gold standard strategy for early-stage patients, but at the same time it could be considered as a valid option in controlling Kaposi’s sarcoma locally advanced lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Electrochemotherapy in Kaposi’s Sarcoma Patients: From the Gold Standard Strategy to Locally Advanced Cutaneous and Subcutaneous Lesions

Rullo,

Castellaneta,

D’Antonio

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…A novel setting to explore these approaches is the treatment of unresectable/borderline resectable skin cancers or soft tissue tumours. Specifically, ECT/Ca-EP could be applied preoperatively to downstage the tumours and allow for subsequent radical resection [ 205 ] or, alternatively, following surgery to ensure sterilisation of residual microscopic disease. Of note, the same concept is being explored with IRE in treating pancreatic cancer (i.e., MA-IRE) [ 12 , 62 , 74 ].…”

Section: Discussionmentioning

confidence: 99%

“…Intriguing data also come from another monocentric experience in 41 patients with primary or secondary malignancies of various histotypes (mostly SCC) and median tumour size of 6 cm, who were deemed at risk of incomplete resection. In this study, ECT was associated with a 55% median reduction of tumour volume, and 25 patients (61%) achieved tumour clearance after surgery, with no relevant surgical morbidity [ 205 ]. Prospective multicentre studies are needed to explore further and standardise this strategy.…”

Section: Electrochemotherapymentioning

confidence: 99%

Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation

Campana

Daud

Lancellotti

et al. 2023

Cancers

View full text Add to dashboard Cite

The 4th World Congress of Electroporation (Copenhagen, 9–13 October 2022) provided a unique opportunity to convene leading experts in pulsed electric fields (PEF). PEF-based therapies harness electric fields to produce therapeutically useful effects on cancers and represent a valuable option for a variety of patients. As such, irreversible electroporation (IRE), gene electrotransfer (GET), electrochemotherapy (ECT), calcium electroporation (Ca-EP), and tumour-treating fields (TTF) are on the rise. Still, their full therapeutic potential remains underappreciated, and the field faces fragmentation, as shown by parallel maturation and differences in the stages of development and regulatory approval worldwide. This narrative review provides a glimpse of PEF-based techniques, including key mechanisms, clinical indications, and advances in therapy; finally, it offers insights into current research directions. By highlighting a common ground, the authors aim to break silos, strengthen cross-functional collaboration, and pave the way to novel possibilities for intervention. Intriguingly, beyond their peculiar mechanism of action, PEF-based therapies share technical interconnections and multifaceted biological effects (e.g., vascular, immunological) worth exploiting in combinatorial strategies.

show abstract

“…In human patients, neoadjuvant ECT has recently shown therapeutic efficacy in cutaneous tumours, allowing good cosmetic results and ensuring a good QoL. 16 The veterinary literature contains reports of ECT achieving local control of advanced feline SCC of the head, with complete response in up to 81% of cases and median time to progression of 20.6 months compared to controls that had a median time to progression of 3.9 months. 15 When taking into consideration only cats with periocular SCC treated with ECT, the median time to progression was 24.2 months; however, no information about tumour stage or precise location within the periocular area was provided.…”

Section: Discussionmentioning

confidence: 99%

“…In human patients, neoadjuvant ECT has recently shown therapeutic efficacy in cutaneous tumours, allowing good cosmetic results and ensuring a good QoL 16 . The veterinary literature contains reports of ECT achieving local control of advanced feline SCC of the head, with complete response in up to 81% of cases and median time to progression of 20.6 months compared to controls that had a median time to progression of 3.9 months 15 .…”

Section: Discussionmentioning

confidence: 99%

Long‐term outcome with neoadjuvant electrochemotherapy and sliding canthoplasty in a cat with locally advanced squamous cell carcinoma of the lower and third eyelid

Ferro

Rigon

Ciccarelli

et al. 2022

Vet Record Case Reports

View full text Add to dashboard Cite

A 10‐year‐old, female, spayed cat was referred with a lower eyelid mass lesion of the right eye. Fine‐needle aspiration cytology and histopathology revealed a locally advanced squamous cell carcinoma. The cat was treated with three sessions of neoadjuvant electrochemotherapy, which was associated with a good response. After electrochemotherapy treatment, a sliding canthoplasty was performed to reconstruct the eyelid margin. Histology of excised tissue during surgery, post‐electrochemotherapy, demonstrated a lack of neoplastic cells. The patient was still in complete remission 22 months after diagnosis. All treatments were well tolerated, with mild‐to‐moderate and self‐limiting local toxicities, allowing normal eyelid function and preservation of sight. This multi‐modal approach resulted in a long‐term local control. This case report highlights the potential benefit of electrochemotherapy in the neoadjuvant setting, enabling surgical removal and long‐term local tumour control.

show abstract

Neoadjuvant treatment by ECT in cutaneous malignant neoplastic lesions

Cited by 7 publications

References 33 publications

Electrochemotherapy in Kaposi’s Sarcoma Patients: From the Gold Standard Strategy to Locally Advanced Cutaneous and Subcutaneous Lesions

Electrochemotherapy in Kaposi’s Sarcoma Patients: From the Gold Standard Strategy to Locally Advanced Cutaneous and Subcutaneous Lesions

Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation

Long‐term outcome with neoadjuvant electrochemotherapy and sliding canthoplasty in a cat with locally advanced squamous cell carcinoma of the lower and third eyelid

Contact Info

Product

Resources

About